Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variantShuai Xia, Shibo Jiang, Jasper Fuk‐Woo Chan et al.|Cell Research|2022Cited by 40
Targeted desialylation and cytolysis of tumour cells by fusing a sialidase to a bispecific T-cell engagerZhuo Yang, Peng Wu, Jaroslav Žák et al.|Nature Biomedical Engineering|2024Cited by 35
Reshaping the tumor microenvironment by degrading glycoimmune checkpoints Siglec-7 and -9Chao Wang, Peng Wu, Yingqin Hou et al.|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 14